Bleakley Financial Group LLC Purchases Shares of 20,318 DexCom, Inc. $DXCM

Bleakley Financial Group LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, HoldingsChannel reports. The fund purchased 20,318 shares of the medical device company’s stock, valued at approximately $1,774,000.

A number of other institutional investors and hedge funds have also bought and sold shares of DXCM. Ethic Inc. grew its position in shares of DexCom by 3.7% during the second quarter. Ethic Inc. now owns 49,205 shares of the medical device company’s stock valued at $4,248,000 after purchasing an additional 1,753 shares in the last quarter. Stephens Investment Management Group LLC grew its position in DexCom by 4.4% in the second quarter. Stephens Investment Management Group LLC now owns 877,832 shares of the medical device company’s stock worth $76,626,000 after acquiring an additional 36,748 shares in the last quarter. Rehmann Capital Advisory Group purchased a new position in DexCom in the second quarter worth about $213,000. Covenant Partners LLC purchased a new position in DexCom in the second quarter worth about $256,000. Finally, D.A. Davidson & CO. grew its position in DexCom by 12.7% in the second quarter. D.A. Davidson & CO. now owns 29,427 shares of the medical device company’s stock worth $2,569,000 after acquiring an additional 3,315 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Activity at DexCom

In other DexCom news, Director Kyle Malady sold 667 shares of the company’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the sale, the director directly owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,849 shares of company stock valued at $564,733 over the last three months. 0.32% of the stock is owned by corporate insiders.

DexCom Stock Performance

Shares of DXCM stock opened at $70.33 on Friday. The business’s fifty day simple moving average is $72.37 and its 200-day simple moving average is $77.78. The company has a market cap of $27.58 billion, a PE ratio of 48.84, a PEG ratio of 1.49 and a beta of 1.47. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business’s quarterly revenue was up 15.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on DXCM shares. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 10th. Argus assumed coverage on DexCom in a research report on Thursday, August 21st. They set a “buy” rating and a $100.00 target price for the company. Cowen reaffirmed a “buy” rating on shares of DexCom in a research report on Friday. William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Finally, Mizuho lifted their price target on shares of DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.19.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.